Audit sterility, regulatory standing, and batch-testing transparency before evaluating a pharmacy.
Warning: Critical safety benchmarks missing. High risk of contamination, sub-potency, or regulatory non-compliance.
The pharmacy is an active state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility adhering to current Good Manufacturing Practices (cGMP).
Medication is dispensed exclusively pursuant to a valid, patient-specific prescription issued by a licensed, board-certified healthcare provider following an interactive clinical consultation.
The provider or pharmacy can furnish a lot-matched third-party HPLC purity assay (demonstrating ≥ 98.0% purity) and Mass Spectrometry confirmation.
The sterile preparation has documented passing results for membrane filtration sterility testing (USP <71>) and Limulus Amebocyte Lysate endotoxin limits (USP <85>).
The Beyond-Use Date does not exceed strict pharmacopeial stability limits (e.g. max 28 days for multi-dose preserved vials post-puncture).
The active peptide is not restricted from compounding under FDA Category 2 safety warnings (such as BPC-157, TB-500, or CJC-1295).
The formulation uses legitimate pharmaceutical base substances rather than unapproved trifluoroacetate (TFA) or unstudied salt derivatives.
The medication is shipped with calibrated temperature-monitoring packs and insulated thermal insulation to prevent heat-induced denaturing.
The vial label clearly specifies exact concentration (mg/mL), preservative content (e.g. 0.9% benzyl alcohol), inactive excipients, and lot identifier.
The dispensing pharmacy provides direct access to a licensed clinical pharmacist (PharmD) to answer administration questions and handle MedWatch reporting.